Overview

A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

Status:
COMPLETED
Trial end date:
2024-09-25
Target enrollment:
Participant gender:
Summary
This study will assess the safety and tolerability of inhaled LTI-03 in treatment nave participants with newly diagnosed IPF.
Phase:
PHASE1
Details
Lead Sponsor:
Rein Therapeutics
Treatments:
Capsules